当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.

Abstract：

BACKGROUND:A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV) therapy for nucleoside analogue-resistant chronic hepatitis B. METHODS:Patients (n=60) were randomized to TDF monotherapy or ETV-ADV combination therapy for 96 weeks. All patients had the rt204I/V mutation and serum HBV DNA was measured (>60 IU/ml) during LAM-ADV therapy. The primary end point was a complete virological response (HBV DNA <20 IU/ml) at week 96. RESULTS:The median duration of prior LAM-ADV rescue therapy was 43 (7-108) months. A complete virological response was achieved in 86.6% and 53.3% of patients in the TDF and ETV-ADV groups, respectively, at week 96 (P=0.005). Reduction in serum HBV DNA was significantly greater in the TDF group than in ETV-ADV group (-3.2 ±1.2 versus -2.6 ±1.2; P=0.01). Hepatitis B e antigen loss (22.2% versus 16.6%; P=0.731) and biochemical responses (76.7% versus 73.3%; P=0.766) were not different between the TDF and ETV-ADV groups. No newly emerged mutations were detected. Both therapies demonstrated favourable safety profiles. CONCLUSIONS:TDF therapy achieved a better complete virological response than ETV-ADV therapy in chronic hepatitis B patients with suboptimal response to long-term LAM-ADV rescue therapy. (KCT0000627).

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Lee SH,Cheon GJ,Kim HS,Kim SG,Kim YS,Jeong SW,Jang JY,Kim BS,Jun BG,Don Kim Y,Jun DW,Sohn JH,Kim TY,Lee BS

doi

10.3851/IMP3169

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

219-227

issue

3

eissn

1359-6535

issn

2040-2058

journal_volume

23

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

ANTIVIRAL THERAPY文献大全
  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract：OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：

    authors： Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期：2007-01-01 00:00:00

  • Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

    abstract：:We assessed the prevalence and clinical impact of insertions within the HIV-1 p6Gag proline-rich (PTAP) region on initial antiretroviral therapy response in 461 HIV-infected, drug-naive individuals initiating therapy in British Columbia, Canada between June 1996 and August 1998. HIV p6Gag insertions were detected by n...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Brumme ZL,Chan KJ,Dong WW,Wynhoven B,Mo T,Hogg RS,Montaner JS,O'Shaughnessy MV,Harrigan PR

    更新日期：2003-04-01 00:00:00

  • Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

    abstract：OBJECTIVES:To characterize 1-year virological response to antiretroviral therapy and its determinants by sex. METHODS:This is a population-based analysis of antiretroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml w...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： O'Connell JM,Braitstein P,Hogg RS,Yip B,Craib KJ,O'Shaughnessy MV,Montaner JS,Burdge DR

    更新日期：2003-12-01 00:00:00

  • Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.

    abstract：:Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章

    doi：

    authors： Chan HL,Wong VW,Hui AY,Tsang SW,Chan JL,Chan HY,Wong GL,Sung JJ

    更新日期：2006-01-01 00:00:00

  • Management of hepatitis B patients with antiviral resistance.

    abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Fung SK,Lok AS

    更新日期：2004-12-01 00:00:00

  • Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.

    abstract：:The effectiveness of current antiretroviral therapies has led to more patients receiving long-term therapy, and increasing numbers of older patients. The complex interactions between HIV infection, ageing, comorbid conditions and drug-related toxicities, and their combined effects on patient health and quality of life...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1470

    authors： Boehme RE,Cameron S

    更新日期：2009-01-01 00:00:00

  • Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infection.

    abstract：BACKGROUND:We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART;...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2745

    authors： Brigham EP,Patil SP,Jacobson LP,Margolick JB,Godfrey R,Johnson J,Johnson-Hill LM,Reynolds S,Schwartz AR,Smith PL,Brown TT

    更新日期：2014-01-01 00:00:00

  • Drug-drug interactions in HIV therapy: is it all clear?

    abstract：:Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2688

    authors： Burger D,Back D

    更新日期：2013-01-01 00:00:00

  • A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

    abstract：BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

    更新日期：2007-01-01 00:00:00

  • Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

    abstract：BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP1931

    authors： Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

    更新日期：2011-01-01 00:00:00

  • Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.

    abstract：BACKGROUND:With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS:Two different real-time PCR platforms, the CO...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2723

    authors： Taylor N,Haschke-Becher E,Greil R,Strasser M,Oberkofler H

    更新日期：2014-01-01 00:00:00

  • Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.

    abstract：BACKGROUND:Hepatitis delta virus (HDV) infection therapy is unclear. This systematic analysis aimed to clarify the evidence on the efficacy of interferon (IFN)-α-based therapy in HDV. METHODS:We performed a systematic search on electronic databases including MEDLINE (1970 to January 2011), Web of Science, The Cochrane...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2306

    authors： Lamers MH,Kirgiz ÖÖ,Heidrich B,Wedemeyer H,Drenth JP

    更新日期：2012-01-01 00:00:00

  • Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.

    abstract：BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Lai MW,Huang SF,Hsu CW,Chang MH,Liaw YF,Yeh CT

    更新日期：2009-01-01 00:00:00

  • Does antiviral therapy prevent hepatocellular carcinoma?

    abstract：:Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1895

    authors： Kwon H,Lok AS

    更新日期：2011-01-01 00:00:00

  • Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

    abstract：BACKGROUND:We examined whether waist circumference (WC) and self-reported abdominal size changes can estimate visceral adipose tissue (VAT) changes for those initiating antiretroviral therapy (ART). METHODS:Prospectively collected data from ACTG A5257 and its metabolic substudy, A5260s, were used for this analysis. AR...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3148

    authors： Bhagwat P,Ofotokun I,McComsey GA,Brown TT,Moser C,Sugar CA,Currier JS

    更新日期：2017-01-01 00:00:00

  • Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

    abstract：BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2671

    authors： Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

    更新日期：2013-01-01 00:00:00

  • Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

    abstract：BACKGROUND:A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in c...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1796

    authors： Kurosaki M,Tanaka Y,Tanaka K,Suzuki Y,Hoshioka Y,Tamaki N,Kato T,Yasui Y,Hosokawa T,Ueda K,Tsuchiya K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Asahina Y,Matsuura K,Sugauchi F,Enomoto N,Nishida N,Tokunaga K,Miz

    更新日期：2011-01-01 00:00:00

  • Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.

    abstract：BACKGROUND:The development of infections with ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) remains a serious problem in recipients of stem cell or organ transplants. Nearly all GCV-resistant clinical isolates have mutations in the viral UL97 gene. The rapid detection of GCV-resistant HCMV infections is nece...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Göhring K,Mikeler E,Jahn G,Rohde F,Hamprecht K

    更新日期：2008-01-01 00:00:00

  • Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.

    abstract：OBJECTIVE:To study decay rates of productively and latently infected cells in peripheral blood and lymph nodes during triple antiretroviral therapy and the possible impact of interleukin-2 (IL-2) on viral kinetics. METHODS:In this non-randomized study, nine antiretroviral-naive HIV-positive patients received either sa...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Stellbrink HJ,Hufert FT,Tenner-Racz K,Lauer J,Schneider C,Albrecht H,Racz P,van Lunzen J

    更新日期：1998-01-01 00:00:00

  • Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.

    abstract：BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2724

    authors： Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

    更新日期：2014-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期：2006-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract：:MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2766

    authors： van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期：2014-01-01 00:00:00

  • HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

    abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP1982

    authors： Kim BK,Revill PA,Ahn SH

    更新日期：2011-01-01 00:00:00

  • Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

    abstract：:Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2222

    authors： Dustin LB,Charles ED

    更新日期：2012-01-01 00:00:00

  • Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.

    abstract：BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Maynard M,Pradat P,Gagnieu MC,Souvignet C,Trepo C

    更新日期：2008-01-01 00:00:00

  • Factors associated with non-adherence to HBV antiviral therapy.

    abstract：BACKGROUND:HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits requir...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP3219

    authors： Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,George J,Zekry A,Maher L

    更新日期：2018-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract：:Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP3245

    authors： Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期：2018-01-01 00:00:00

  • Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.

    abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Grollo L,Torresi J,Drummer H,Zeng W,Williamson N,Jackson DC

    更新日期：2006-01-01 00:00:00

  • A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.

    abstract：BACKGROUND:Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination a...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Fox Z,Dragsted UB,Gerstoft J,Phillips AN,Kjaer J,Mathiesen L,Youle M,Katlama C,Hill A,Bruun JN,Clumeck N,Dellamonica P,Lundgren JD,COLATE study group.

    更新日期：2006-01-01 00:00:00

  • Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

    abstract：OBJECTIVE:A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence. DESIGN:Prospective randomized 1-year trial. SETTING:Collaboration of HI...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Weber R,Christen L,Christen S,Tschopp S,Znoj H,Schneider C,Schmitt J,Opravil M,Günthard HF,Ledergerber B,Swiss HIV Cohort Study.

    更新日期：2004-02-01 00:00:00